BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

12:00 AM
 | 
Nov 02, 2009
 |  BioCentury  |  Finance

EPS watch

EPS watch

Company 3Q09 EPS est 3Q09 EPS actual Outcome Growth from 3Q08 10/30 cls Wk chg % chg Mcap chg 10/30 Mcap
AstraZeneca plc (LSE:AZN; NYSE:AZN) NA $1.68 NA 27% $44.91 -$0.27 -1% -$391.5 $65,119.5
3Q09 revenues increased 5% to $8.2B from $7.8B in 3Q08. The pharma also raised its core EPS guidance for 2009 to $6.20-$6.40 from $5.70-$6. Figures include a negative foreign currency exchange impact.
Bayer AG (Xetra:BAY) NA Â 0.30 NA -3% Â 47.23 - 0.59 -1% -$733.6 $58,721.8
Sales in Bayer's Pharmaceutical segment increased 3% in 3Q09 over 3Q08 to €2.5B ($3.7B). Overall, 3Q09 sales fell 7% to €7.4M ($10.8B) from €7.9B in 3Q08. The Street was expecting €7.5B. Figures include a negative foreign currency exchange impact.
BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) $0.01 $0.06 Beat by $0.05 500% $15.56 -$1.44 -8% -$144.5 $1,561.2
3Q09 revenues increased 11% to $80.8M from $72.6M in 3Q08. 3Q09 sales of Naglazyme galsulfase to treat mucopolysaccharidosis VI (MPS VI) were $42.1M, up...

Read the full 1225 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury

Article Purchase

$150 USD
More Info >